OT Broadcast News
OT Broadcast News
Oncology Times
The Disappointment of the NSABP C-08 Trial
9 minutes Posted Oct 13, 2009 at 12:03 am.
0:00
9:05
Download MP3
Show notes

Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli